Transaction
Laprophan Group acquires majority stake in Rivopharm
- Announced
- 25 June 2026
- Target
- Rivopharm SA
- Value
- Undisclosed
- Asset class
- Corporate Transactions
- Type
- Merger/Acquisition(M&A)
- Instrument
- Ordinary Shares (Equity)
- Lead investors
- Laprophan S.A
- Investors
- Laprophan S.A
- Sector
- Healthcare / Biotechnology, Pharmaceuticals
About the target
Rivopharm SA is a Switzerland-based pharmaceutical manufacturer specialising in generic medicines, specialty pharmaceutical formulations, dossier development, and value-added pharmaceutical solutions. Incorporated in 1961 and headquartered in Manno, Canton Ticino, the company develops and manufactures oral solid dosage forms, primarily tablets and capsules, and manages a proprietary portfolio of approximately 125 molecules and nearly 1,500 SKUs distributed across more than 30 countries. Rivopharm operates an FDA-, TGA-, Swissmedic- and EU-approved manufacturing facility in Manno and maintains subsidiaries in the United Kingdom, Germany, and Lithuania.
Sources
- www.mcapitalp.com
- Partner Researchers